Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion
Jacob S. Bowers(Medical University of South Carolina), Chrystal M. Paulos(Medical University of South Carolina)
Cited by 69
Related Papers
Th17 Cells in Cancer: The Ultimate Identity Crisis
|Frontiers in Immunology|2014|327
Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 <sup>+</sup> T cells
|European Journal of Immunology|2020|64